Department of Hematology, Lymphoma Research Center, Peking University Third Hospital, 100191, Beijing, China.
Melbourne School of Population and Global Health, The University of Melbourne, Melbourne, VIC, 3010, Australia.
Cancer Gene Ther. 2019 Nov;26(11-12):347-355. doi: 10.1038/s41417-018-0070-x. Epub 2019 Jan 9.
Multiple myeloma (MM) is one of hematological malignancies, characterized by malignant proliferation of plasma cells. Biomarkers play an important role in evaluating the development and prognosis of MM. Ubiquitin-conjugating enzyme E2T (UBE2T) is served to connect with particular E3 ubiquitin ligase to degraded-related substrates, contributing to DNA repair in the Fanconi anemia pathway. Also, numerous evidences reported that UBE2T is closely related to cell proliferation and carcinogenesis. However, the relationship between MM and UBE2T has not been studied. Here, we integrated eight datasets and analyzed the relationship of expression of UBE2T and ISS, 1q21, relapse and survival in MM 2684 patients (totally 2893 samples). We found that the expression of UBE2T increased with the deterioration of MM (P = 1.4e-07), especially in the early stage. UBE2T is closely related to IgG serotype MM (P = 6.9e-05). High expression of UBE2T is associated with poor survival and prognosis (EFS: P = 1.43e-03, OS: P = 5.47e-05). UBE2T is likely to play a part in the cell division pathway, affecting the survival and prognosis of MM. Therefore, UBE2T could be considered as an early alternative biomarker for the prognosis of MM.
多发性骨髓瘤（MM）是一种血液系统恶性肿瘤，其特征是浆细胞的恶性增殖。生物标志物在评估 MM 的发展和预后方面起着重要作用。泛素结合酶 E2T（UBE2T）用于与特定的 E3 泛素连接酶连接，以降解相关底物，有助于范可尼贫血途径中的 DNA 修复。此外，大量证据表明 UBE2T 与细胞增殖和癌变密切相关。然而，MM 和 UBE2T 之间的关系尚未得到研究。在这里，我们整合了八个数据集，分析了 2684 名 MM 患者（共 2893 个样本）中 UBE2T 的表达与 ISS、1q21、复发和生存之间的关系。我们发现 UBE2T 的表达随着 MM 的恶化而增加（P=1.4e-07），尤其是在早期。UBE2T 与 IgG 血清型 MM 密切相关（P=6.9e-05）。UBE2T 的高表达与不良的生存和预后相关（EFS：P=1.43e-03，OS：P=5.47e-05）。UBE2T 可能在细胞分裂途径中发挥作用，影响 MM 的生存和预后。因此，UBE2T 可以被认为是 MM 预后的早期替代生物标志物。
